SCHEMBL1104588

SCHEMBL1104588

CC(C)n1cc2c(nc1=O)[nH]c1ccccc12

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 8/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
CA5A P35218 1/20 0.43
HAVCR2 Q8TDQ0 2/20 0.41
ADORA3 P0DMS8 4/20 0.39
ADORA1 P30542 2/20 0.39
HSD17B10 Q99714 4/20 0.39
LMNA P02545 3/20 0.39
GPR3 P46089 2/20 0.39
KDM4E B2RXH2 2/20 0.39
MEN1 O00255 1/20 0.39
TNKS O95271 1/20 0.39
CYP1A2 P05177 1/20 0.39
PARP1 P09874 1/20 0.39
BLM P54132 1/20 0.39
PMP22 Q01453 1/20 0.39
KMT2A Q03164 1/20 0.39
PARP15 Q460N3 1/20 0.39
TNKS2 Q9H2K2 1/20 0.39
HPGD P15428 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1104590 0.92 ALDH1A1 (0.46) ALDH1A1L3MBTL1CA5AHAVCR2HSD17B10
SCHEMBL14183841 0.81 AURKA (0.46) ALDH1A1ADORA1KDM4ECYP1A2PARP1
SCHEMBL13395617 0.80 CA5A (0.50) ALDH1A1CA5AHAVCR2ADORA3ADORA1
SCHEMBL23841188 0.77 CA5A (0.43) ALDH1A1CA5AHAVCR2ADORA3ADORA1
SCHEMBL18080609 0.74 LCK (0.30) KDM4EKMT2A
SCHEMBL18080432 0.73 JAK1 (0.38) ALDH1A1HSD17B10LMNAKDM4ECYP1A2
SCHEMBL18080431 0.73 KDM4E (0.39) ALDH1A1KDM4EKMT2AHPGDGLA
SCHEMBL18080601 0.73
SCHEMBL18080584 0.72 ADORA1 (0.48) ALDH1A1ADORA1HSD17B10LMNAKDM4E
SCHEMBL18080600 0.72

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8541599-B2 Supports for oligomer synthesis ISIS PHARMACEUTICALS, INC. (US) 2013-09-24 US disclosed
US-20120165547-A1 SUPPORTS FOR OLIGOMER SYNTHESIS ISIS PHARMACEUTICALS, INC. (US) 2012-06-28 US disclosed
US-8153725-B2 Supports for oligomer synthesis ISIS PHARMACEUTICALS, INC (US) 2012-04-10 US disclosed
US-7939677-B2 Oligomeric compounds comprising 4′-thionucleosides for use in gene modulation ISIS PHARMACEUTICALS, INC. (US) 2011-05-10 US disclosed
US-7875733-B2 Nucleosides; RNA interference; gene expression inhibition; for use in therapeutic, diagnostic, and research applications involving gene silencing ISIS PHARMACEUTICALS, INC. (US) 2011-01-25 US disclosed
US-20100324277-A1 OLIGOMERIC COMPOUNDS COMPRISING 4'-THIONUCLEOSIDES FOR USE IN GENE MODULATION ISIS PHARMACEUTICALS, INC. (US) 2010-12-23 US disclosed
US-20100234528-A1 SUPPORTS FOR OLIGOMER SYNTHESIS ISIS PHARMACEUTICALS, INC. (US) 2010-09-16 US disclosed
US-7759480-B2 Chloral-free DCA in oligonucleotide synthesis ISIS PHARMACEUTICALS, INC. (US) 2010-07-20 US disclosed
US-7718810-B2 Supports such as glass and styrene polymers functionalized with tricyclic hetercyclic anhydrides and imides, used in the preparation of oligonucleotides ISIS PHARMACEUTICALS, INC. (US) 2010-05-18 US disclosed
US-7713944-B2 Oligomers comprising activated disulfides which bind to plasma proteins and their use for delivery to cells ISIS PHARMACEUTICALS, INC. (US) 2010-05-11 US disclosed
US-7576119-B2 Supports for oligomer synthesis ISIS PHARMACEUTICALS, INC. (US) 2009-08-18 US disclosed
US-20090131682-A1 SUPPORTS FOR OLIGOMER SYNTHESIS ISIS PHARMACEUTICALS, INC. (US) 2009-05-21 US disclosed
US-7427675-B2 Compounds and methods for the characterization of oligonucleotides ISIS PHARMACEUTICALS, INC. (US) 2008-09-23 US disclosed
US-20080097028-A1 POLYMERIC BEADS FOR OLIGOMER SYNTHESIS LSIS PHARMACEUTICALS, INC. (US) 2008-04-24 US disclosed
US-7348391-B2 Polymeric beads for oligomer synthesis ISIS PHARMACEUTICALS, INC. (US) 2008-03-25 US disclosed
US-20080021224-A1 SUPPORTS FOR OLIGOMER SYNTHESIS ISIS PHARMACEUTICALS, INC. (US) 2008-01-24 US disclosed
US-7276599-B2 Oligonucleotide synthesis with alternative solvents ISIS PHARMACEUTICALS, INC. (US) 2007-10-02 US disclosed
US-20070123703-A1 CHLORAL-FREE DCA IN OLIGONUCLEOTIDE SYNTHESIS ISIS PHARMACEUTICALS, INC. (US) 2007-05-31 US disclosed
US-7202264-B2 Supports such as glass and styrene polymers functionalized with tricyclic hetercyclic anhydrides and imides, used in the preparation of oligonucleotides ISIS PHARMACEUTICALS, INC. (US) 2007-04-10 US disclosed
US-7169916-B2 Chloral-free DCA in oligonucleotide synthesis ISIS PHARMACEUTICALS, INC. (US) 2007-01-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090131682-A1 SUPPORTS FOR OLIGOMER SYNTHESIS ILK, NOP2, PFAS ALDH1A1 4121/4885L3MBTL1 2447/4885CA5A 4022/4885
US-20080097028-A1 POLYMERIC BEADS FOR OLIGOMER SYNTHESIS NEFM, NOD2, MACF1 ALDH1A1 4011/4885L3MBTL1 4186/4885CA5A 3716/4885
US-20120165547-A1 SUPPORTS FOR OLIGOMER SYNTHESIS ILK, NOP2, PFAS ALDH1A1 4121/4885L3MBTL1 2447/4885CA5A 4022/4885
US-20080021224-A1 SUPPORTS FOR OLIGOMER SYNTHESIS ILK, NOP2, PFAS ALDH1A1 4121/4885L3MBTL1 2447/4885CA5A 4022/4885
US-20100324277-A1 OLIGOMERIC COMPOUNDS COMPRISING 4'-THIONUCLEOSIDES FOR USE IN GENE MODULATION SNRPE, NSUN3, NSUN2 ALDH1A1 4066/4885L3MBTL1 336/4885CA5A 4003/4885
US-20100234528-A1 SUPPORTS FOR OLIGOMER SYNTHESIS ILK, NOP2, PFAS ALDH1A1 4121/4885L3MBTL1 2447/4885CA5A 4022/4885
US-20070123703-A1 CHLORAL-FREE DCA IN OLIGONUCLEOTIDE SYNTHESIS DCLRE1B, DCTD, DDT ALDH1A1 1166/4885L3MBTL1 967/4885CA5A 248/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.